{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:18:04Z","timestamp":1794565084974,"version":"4.9.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T00:00:00Z","timestamp":1072742400000},"content-version":"vor","delay-in-days":455,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Marat\u00f3 Fundaci\u00f3 TV3","award":["U-2000-TV2710"],"award-info":[{"award-number":["U-2000-TV2710"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["FIS 00\/0616"],"award-info":[{"award-number":["FIS 00\/0616"]}]},{"name":"Direcci\u00f3n General de Investigaci\u00f3n Cient\u00edfico y T\u00e9cnica","award":["SAF 2001\/0300"],"award-info":[{"award-number":["SAF 2001\/0300"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria"},{"name":"Instituto Reina Sof\u00eda de Investigaci\u00f3n Nefrol\u00f3gica"},{"name":"Hospital Cl\u00ednic"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Vasopressin analogues associated with albumin improve renal function in hepatorenal syndrome (HRS). The current study was aimed at assessing the efficacy of the treatment, predictive factors of response, recurrence of HRS, and survival after therapy. Twenty-one consecutive patients with HRS (16 with type 1 HRS, 5 with type 2 HRS) received terlipressin (0.5-2 mg\/4 hours intravenously) until complete response was achieved (serum creatinine level &lt; 1.5 mg\/dL) or for 15 days; 13 patients received intravenous albumin together with terlipressin. Twelve of the 21 patients (57%) showed complete response. Albumin administration was the only predictive factor of complete response (77% in patients receiving terlipressin and albumin vs. 25% in those receiving terlipressin alone, <jats:italic toggle=\"yes\">P<\/jats:italic> = .03). Treatment with terlipressin and albumin was associated with a remarkable decrease in serum creatinine level, increase in arterial pressure, and suppression of the renin-aldosterone system. By contrast, no significant changes in these parameters were found in patients treated with terlipressin alone. Only 1 patient showed ischemic adverse effects. Recurrence of HRS occurred in 17% of patients with complete response. The occurrence of complete response was associated with an improved survival. In conclusion, terlipressin therapy reverses HRS in a high proportion of patients. Recurrence rate after treatment withdrawal is uncommon. Albumin appears to improve markedly the beneficial effects of terlipressin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1053\/jhep.2002.35819","type":"journal-article","created":{"date-parts":[[2003,3,26]],"date-time":"2003-03-26T02:15:53Z","timestamp":1048644953000},"page":"941-948","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":435,"title":["Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study"],"prefix":"10.1097","volume":"36","author":[{"given":"Rolando","family":"Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gin\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Uriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blas","family":"Calahorra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara","family":"De Las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladimiro","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rod\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1053\/jhep.2002.35819-BIB1|cit1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1053\/gast.2002.33575","article-title":"Hepatorenal syndrome","volume":"122","author":"Arroyo","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2002.35819-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/jhep.2001.29200","article-title":"New challenge of hepatorenal syndrome: prevention and treatment","volume":"34","author":"Wong","year":"2001","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB4|cit4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Gin\u00e8s","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2002.35819-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB6|cit6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"1","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB7|cit7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine","volume":"30","author":"G\u00fclberg","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB8|cit8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2002.35819-BIB9|cit9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2002.35819-BIB10|cit10","first-page":"15","article-title":"Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1053\/jhep.2002.35819-BIB11|cit11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2002.35819-BIB12|cit12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0016-5085(90)91303-N","article-title":"Total paracentesis associated with intravenous albumin in the management of patients with cirrhosis and ascites","volume":"98","author":"Tit\u00f3","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2002.35819-BIB13|cit13","first-page":"87","volume-title":"The Kidney in Liver Disease","author":"Papper","year":"1983"},{"key":"10.1053\/jhep.2002.35819-BIB14|cit14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ki.1986.249","article-title":"Peritoneovenous shunt in the management of the hepatorenal syndrome","volume":"30","author":"Linas","year":"1986","journal-title":"Kidney Int"},{"key":"10.1053\/jhep.2002.35819-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB16|cit16","first-page":"492","volume-title":"Ascites and Renal Dysfunction in Liver Disease","author":"Arroyo","year":"1999"},{"key":"10.1053\/jhep.2002.35819-BIB17|cit17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","article-title":"Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems","volume":"28","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB18|cit18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.47.2.288","article-title":"Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study","volume":"47","author":"Brensing","year":"2000","journal-title":"Gut"},{"key":"10.1053\/jhep.2002.35819-BIB19|cit19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00007890-199102000-00030","article-title":"Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients","volume":"51","author":"Gonwa","year":"1991","journal-title":"Transplantation"},{"key":"10.1053\/jhep.2002.35819-BIB20|cit20","volume-title":"Fachinformation: Glycylpressin R, terlipressin acetate","year":"1996"},{"key":"10.1053\/jhep.2002.35819-BIB21|cit21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/jhep.2000.16601","article-title":"Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study","volume":"32","author":"Escorsell","year":"2000","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2002.35819-BIB22|cit22","unstructured":"Ioannou GN Doust J Rockey DC Terlipressin for acute esophageal variceal hemorrhage: a systematic review and meta-analysis. Medline Embase, Cochrane Controlled Trials Register, Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Library www.cochrane.org"},{"key":"10.1053\/jhep.2002.35819-BIB23|cit23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0168-8278(01)00031-9","article-title":"Live donor liver transplantation","volume":"34","author":"Pomfret","year":"2001","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2002.35819-BIB24|cit24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0016-5085(87)90327-1","article-title":"Effects of renal impairment on liver transplantation","volume":"93","author":"Rimola","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2002.35819-BIB25|cit25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pretransplant renal function on survival after liver transplantation","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"10.1053\/jhep.2002.35819-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/jhep.2002.33160","article-title":"Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjhep.2002.35819","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjhep.2002.35819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200210000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:06:10Z","timestamp":1738944370000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200210000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002]]}},"URL":"https:\/\/doi.org\/10.1053\/jhep.2002.35819","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}